Stephen Lam Chan, MD, FRCP, MRCP, on HCC: Pembrolizumab After Resection or Local Ablation
2026 ASCO GI
Stephen Lam Chan, MD, FRCP, MRCP, of the Hong Kong Cancer Institute, The Chinese University of Hong Kong, discusses findings from the phase III KEYNOTE-937 trial, which evaluated the efficacy and safety of pembrolizumab vs placebo as adjuvant therapy in patients with hepatocellular carcinoma (HCC) who had undergone surgical resection or local ablation with curative intent (Abstract 477).
The ASCO Post Staff
Elizabeth Smyth, MD, of the Oxford NIHR Biomedical Research Centre, Churchill Hospital, presents findings from an analysis of the MATTERHORN trial, a phase III study that examined fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) plus durvalumab in patients with resectable gastric/gastroesophageal junction cancer. Dr. Smyth discusses rates of FLOT discontinuation along with event-free survival based on FLOT completion status in the trial (Abstract 343).
The ASCO Post Staff
Ghassan K. Abou-Alfa, MD, of Memorial Sloan Kettering Cancer Center, reviews the goals of the upcoming phase III ARTEMIDE-HCC01 trial, which will examine the efficacy and safety of rilvegostomig (a novel bispecific anti–PD-1/anti-TIGIT antibody) plus bevacizumab with or without tremelimumab as first-line treatment for unresectable hepatocellular carcinoma (Abstract TPS612).
The ASCO Post Staff
Daniela Molena, MD, of Memorial Sloan Kettering Cancer Center, discusses a comparison of the surgical journeys of patients with resectable gastric/gastroesophageal adenocarcinoma who either received fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) plus durvalumab or FLOT plus placebo in the MATTERHORN study (Abstract 353).
The ASCO Post Staff
Matthew Strickland, MD, of Massachusetts General Hospital, reviews results from the phase IIb TERRIFIC trial, which compared the efficacy and safety of the PD-1 inhibitor tislelizumab plus chemoradiotherapy vs chemoradiotherapy or chemotherapy alone in the neoadjuvant treatment of patients with gastric or gastroesophageal junction adenocarcinoma (Abstract 286).
The ASCO Post Staff
Dina Ioffe, MD, of Fox Chase Cancer Center, describes the results of an analysis that sought to determine how race/ethnicity, insurance status, and socioeconomic status may affect patterns of systemic treatment for metastatic hepatocellular carcinoma (HCC) (Abstract 489).
